HALO  valuation analysis

Basics
Name: Halozyme Therapeutics, Inc
Description: Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 10, 2021
Market cap: $6.18B (397th)
Sales(TTM): $331.26M (757th)
Earnings(TTM): $163.08M (417th)

Value
FFER: 1.98 (why)
Actual price: $43.10
FFEThis is Halozyme Therapeutics, Inc's the estimated price. FFEs are the denominator of the FFER ratio.: $20.87
Quantile: HALO is very expensive given its fundamentals.
Prices as of EOD 2021-06-16
Price & Estimates
Sales & Earnings history (TTM)
Notable
  • Halozyme Therapeutics, Inc's earnings increased from -$80.14M to $163.08M in the last year.
  • Halozyme Therapeutics, Inc's sales grew by 101.5% ($164.40M to $331.26M) over one year against a market average growth of 6.5%.
  • Halozyme Therapeutics, Inc's operating income increased from -$73.80M to $198.21M in the last year.
Earnings / MarketCap
Halozyme Therapeutics, Inc
"Biotechnology" industry
Sales / MarketCap
Halozyme Therapeutics, Inc
"Biotechnology" industry
Book / MarketCap
Halozyme Therapeutics, Inc
"Biotechnology" industry
Equity / Assets
Halozyme Therapeutics, Inc
"Biotechnology" industry